Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  OTC Bulletin Board  >  IntelGenx Technologies Corp.    IGX

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2016 5,27 M
EBIT 2016 -0,28 M
Net income 2016 -0,41 M
Debt 2016 -
Yield 2016 -
Sales 2017 6,02 M
EBIT 2017 -0,33 M
Net income 2017 -0,42 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales2016 9,34x
Capi. / Sales2017 8,19x
Capitalization 49,2 M
More Financials
Company
IntelGenx Technologies Corp. operates as a drug delivery company.It focuses on the development of novel, orally administered drug delivery products based on its proprietary oral drug delivery technologies.The company is a provider of product development services for the pharmaceutical industry,... 
Sector
Pharmaceuticals
Calendar
11/09Earnings Release
More about the company
Surperformance© ratings of IntelGenx Technologies Cor
Trading Rating : - Investor Rating :
More Ratings
Latest news on INTELGENX TECHNOLOGIES COR
08/22 INTELGENX TECHNOLOGIES CORP. : Other Events (form 8-K)
08/22 INTELGENX TECHNOLOGIES : Announces Successful Clinical Study for Montelukast for..
08/22 INTELGENX TECHNOLOGIES : Announces Successful Clinical Study for Montelukast for..
08/15 SWK : Intelgenx reports second quarter 2016 financial results and appointment of..
08/12 INTELGENX TECHNOLOGIES : reports 2Q loss
08/11 INTELGENX TECHNOLOGIES CORP. : Management's Discussion and Analysis of Financial..
08/11 INTELGENX TECHNOLOGIES CORP. : Change in Directors or Principal Officers, Other ..
08/11 INTELGENX TECHNOLOGIES : Reports Second Quarter 2016 Financial Results and Appoi..
08/11 INTELGENX TECHNOLOGIES : Reports Second Quarter 2016 Financial Results and Appoi..
08/09 SWK : Intelgenx announces sale of forfivo xl royalty for $6 million
More news
Sector news : Generic Pharmaceuticals
08/25 FTSE retreats as pharma stocks fall
08/25DJStocks Fall as Investors Look to Fed's Jackson Hole Meeting
08/25DJStocks Fall as Investors Look to Fed's Jackson Hole Meeting
08/25DJStocks Fall as Investors Look to Fed's Jackson Hole Meeting -- 3rd Update
08/25DJMylan Boosts Price Assistance for EpiPen Amid Backlash
More sector news : Generic Pharmaceuticals
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus BUY
Number of Analysts 1
Average target price 1,50 $
Spread / Average Target 94%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Horst G. Zerbe Chairman, President & Chief Executive Officer
André Godin Chief Financial Officer & Executive Vice President
Nadine Paiement Director-Research & Development
Bernd Josef Melchers Independent Director
John Archibald Troup Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
INTELGENX TECHNOLOGIES..54
SUN PHARMACEUTICAL IND..-5.88%27 613
OTSUKA HOLDINGS CO LTD6.76%25 779
ONO PHARMACEUTICAL CO...-35.19%16 843
BIOMARIN PHARMACEUTICA..-9.35%16 246
ASPEN PHARMACARE HOLDI..17.77%11 536
More Results